Abstract
Human African Trypanosomiasis (HAT),which is also known as sleeping sickness, is a major cause of death and disability in 36 countries in sub-Saharan Africa. The disease is caused by the protozoan parasite of the Trypanosoma genus which is transmitted by the bite of the tsetse fly. The two types of HAT, the East African form due to Trypanosoma b.rhodesiensei (T. b.rhodesiensi) and the West African form due to T. b.gambiense, differ in their tempo of infection but in both cases the disease is always fatal if untreated. As well as multiple systemic features seen in the early (haemolymphatic) stage of disease, the late (encephalitic stage) stage, is associated with a wide range of neurological features including neuropsychiatric, motor and sensory abnormalities. Accurate staging of the disease is absolutely essential because of the potentially fatal complications of melarsoprol treatment of late–stage disease, the most important of which is a severe post–treatment reactive encephalopathy (PTRE) the pathogenesis of which is not fully understood. However, there is not a universal consensus as to how latestage disease should be diagnosed using CSF criteria, and this has been very problematic in HAT. A more recent alternative drug for late stage gambiense disease is eflornithine (DFMO). There is a pressing need for a non–toxic oral drug for both early and late stage disease that would obviate many of the problems of staging, and various possible strategies to achieve this goal are currently underway. However, control of the disease will also require more effective measures of reducing man/fly contact and also the allocation of much greater financial and infrastructural resources than are currently available in Africa.
Similar content being viewed by others
References
Vickerman K (1997) Landmarks in trypanosome research. In: Hide G, Mottram JC, Coombs GH, Holmes PH (eds) Trypanosomiasis and leishmaniasis. Cab International, Oxford, pp 1–37
Williams BI (1996) African trypanosomiasis. In: Cox FEAG (ed) The Wellcome Trust illustrated history of tropical diseases. The Wellcome Trust, London, pp 178–191
Atouguia JLM, Kennedy PGE (2000) Neurological aspects of human African trypanosomiasis. In: Davis LE, Kennedy PGE (eds) Infectious diseases of the nervous system. Butterworth-Heinemann, Oxford. pp 321–372
Kennedy PGE (2004) Human African trypanosomiasis of the CNS: current issues and challenges. J Clin Invest 113:496–504
Kuzoe FA (1993) Current situation of African trypanosomiasis. Acta Tropica 54:153–162
Donelson JE (2002) Antigenic variation and the African trypanosome genome. Acta Tropica 85:391–404
Barry JD (1997) The biology of antigenic variation in African trypanosomes. In: Hide G, Mottram JC, Coombs GH, Holmes PH (eds) Trypanosomiasis and leishmaniasis. Cab International, Oxford, pp 89–107
Apted FIC (1970) Clinical manifestations and diagnosis of sleeping sickness. In: Mulligan HW (ed) The African trypanosomiasis. George Allen and Unwin, London, pp 661–683
Duggan AJ, Hutchington MP (1966) Sleeping sickness in Europeans: a review of 109 cases. J Trop Med Hyg 69:124–131
Pepin J, Milord F (1994) The treatment of human African trypanosomiasis. Adv Parasitol 33:1–47
(1998) Control and surveillance of African trypanosomiasis. Report of a WHO expert committee. World Health Organization. Geneva, Switzerland, Technical Report Series No. 881, 114 pp
Lejon V, Reiber H, Legros D, Djé N, Magnus E, Wouters I, Sindic CJM, Büscher P (2003) Intrathecal immune response pattern for improved diagnosis of central nervous systems involvement in trypanosomiasis. J Infect Dis 187:1475–1483
Lejon V, Legros D, Richer M, Ruiz JA, Jamonneau V, Truc P, Doua F, Djé N, N’Siesi FX, Bisser S, Magnus E, Wouters I, Konings J, Vervoort T, Sultan F, Büscher P (2002) IgM quantification in the cereprospinal fluid of sleeping sickness patients by a latex card agglutination test. Trop Med Int Health 7:685–692
Chappuis F, Loutan L, Simarro P, Lejon V, Büscher P (2005) Options for field diagnosis of Human African Typanosomiasis. Clin Microbiol Rev 18:133–146
Solano P, Jamonneau V, N’Guessan P, N’Dri L, Djé NN, Miezan TW, Lejon V, Büscher P, Garcia A (2002) Comparison of different DNA preparation protocols for PCR diagnosis of human African trypanosomiasis in Cote d’Ivoire. Acta Tropica 82:349–356
Fairlamb AH (1990) Future prospects for the chemotherapy of human trypanosomiasis. 1. Novel approaches to the chemotherapy of trypanosomiasis. Trans R Soc Trop Med Hyg 84:613–617
Pepin J, Guern C, Ethier L, Milord F, Mpia B, Mansinsa D (1989) Trial of prednisolone for prevention of melarsoprol induced encephalopathy in gambiense sleeping sickness. Lancet 1:1246–1249
Schmid C, Richer M, Bilenge CMM, Josenando T, Chappuis F, Manthelot CR, Nangouma A, Doua F, Asumu PN, Simarro PP, Burri C for the IMPAMEL 11 Study (2005) Effectiveness of a 10- day melarsoprol schedule for the treatment of late-stage human African Trypanosomiasis: confirmation from a multinational study (IMPAMEL 11). J Infect Dis 191:1922–1931
Legros D, Evans S, Maiso F, Enyaru JCK, Mbulamberi D (1994) Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Trans R Soc Trop Med Hyg 93:439–442
Burri C, Brun R (2003) Eflornithine for the treatment of human African trypanosomiasis. Parasitol Res 90 (Suppl 1):S49–S52
Kennedy PGE, Murray M, Jennings F, Rodgers J (2002) Sleeping sickness: new drugs from old? Lancet 359:1695–1696
Kennedy PGE (1999) The pathogenesis and modulation of the post-treatment reactive encephalopathy in a mouse model of human African trypanosomiasis. J Neuroimmunol 100:36–41
MacLean L, Odiit M, Sternberg JM (2001) Nitric oxide and cytokine synthesis in human African trypanosomiasis. J Infect Dis 184:1086–1090
Lejon V, Lardon J, Kenis G, Pinoges L, Legros D, Bisser S, N’Siesi X, Bosmans E, Büscher P (2002) Interleukin (IL)-6, IL-8 and IL-10 in serum and CSF of Trypanaosoma brucei gambiense sleeping sickness patients before and after treatment. Trans R Soc Trop Med Hyg 96:329–333
Kennedy PGE, Rodgers J, Jennings F, Murray M, Leeman S, Burke JM (1997) A substance P antagonist, RP-67.580 amelioarates a mouse meningoencephalitic response to Trypanosoma brucei brucei. Proc Natl Acad Sci USA 94:4167–4170
Kennedy PGE, Rodgers J, Bradley B, Hunt SP, Gettinby G, Leeman S, de Felipe C, Murray M (2003) Clinical and neuroinflammatory responses to meningoencephalitis in Substance P receptor knockout mice. Brain 126:1683–1690
Jennings FW, Gichuki CW, Kennedy PGE, Rodgers J, Hunter CA, Murray M, Burke JM (1997) The role of the polyamine inhibitor eflornithine in the neuropathogenesis of experimental murine African trypanosomiasis. Neuropathol Appl Neurobiol 23:225–234
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kennedy, P.G.E. Human African trypanosomiasis–neurological aspects. J Neurol 253, 411–416 (2006). https://doi.org/10.1007/s00415-006-0093-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-006-0093-3